The present invention relates to an antibody-fluorescent dye conjugate capable of cancer cell-specific fluorescence imaging diagnosis, wherein the fluorescent dye comprises a covalently labeled antibody and is structured to be quenched by interaction with an amino acid residues in the antibody, selected from the group consisting of tryptophan, tyrosine, histidine, and methionine, and to be dequenched upon binding of the antibody to an antigen present on a cell surface to emit fluorescence, whereby cells having a target antigen thereon can be imaged for diagnosis. When using the antibody-fluorescent dye conjugate according to the present invention, in vitro cell assays, high-throughput screening of cells, and cytodiagnosis based on microfluidics exhibit the effect of detecting the presence of cancer cells having a specific antigen expressed thereon at high specificity and sensitivity without a washing process, and can detect the position of primary and metastatic cancer cells at high contrast within a short time, thereby enhancing the accuracy of fluorescent image-guided surgeries and a therapeutic effect.

The present invention relates to a method of disinfecting a region, in particular a skin region of a patient, wherein the method comprises the following steps: a) Application of an optically effective substance to the region; and b) Application of a disinfectant to the region, wherein the optically effective substance and the disinfectant are configured such that the optically effective substance is removed by the disinfectant or its optical properties are changed by the disinfectant.

A ferumoxytol-based dual-modality imaging probe for long-term stem cell tracking through MRI and early diagnosis of cell apoptosis through simultaneous fluorescence imaging is provided. Specifically, a ferumoxytol-based dual-modality imaging probe is provided with enhanced T.sub.2* relaxivity for tracking stem cells through magnetic resonance imaging and detecting apoptotic stem cells through fluorescence imaging.

The present invention relates to diagnostic and therapeutic agents comprising recombinant antibody fragments to bind a protein associated with cancer and methods of use of these diagnostic and therapeutic agents.

Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.

Provided is a glucose derivative, which is taken into cells via a membrane sugar transport system and is represented by formula (1). Also provided are an imaging agent and an imaging method for a cell or intracellular molecule using said glucose derivative. Further provided is a method for detecting cancer cells with good accuracy using said glucose derivative and an imaging agent to be used in said method. More specifically provided are D-glucose derivatives and L-glucose derivatives in which glucose is bound to the 7-position of a fluorescent molecular group with a coumarin backbone or a quinolone backbone. Also provided are a cell imaging agent and imaging method using the derivative. A cancer cell imaging agent and imaging method using the L-glucose derivative is also provided. G is a group selected from formulas (G1)-(G4) below.

The present invention discloses fluorescent compounds and a method for their use for selective imaging of blood vessels and blood flow. By applying these fluorescent compounds and the imaging process to a zebrafish model, the present invention further provides methods and procedures for the discovery, selection, and characterization of pro- and anti-angiogenic agents.

A fluorescent probe for binding to and detection of AP sites of DNA includes the following formula: F-L-X where F is a fluorescent moiety, X is an aminooxy group (ONH.sub.2), and L is a linker that links or couples the fluorescent moiety to the oxyamine.

A ferumoxytol-based dual-modality imaging probe for long-term stem cell tracking through MRI and early diagnosis of cell apoptosis through simultaneous fluorescence imaging is provided. Specifically, a ferumoxytol-based dual-modality imaging probe is provided with enhanced T.sub.2* relaxivity for tracking stem cells through magnetic resonance imaging and detecting apoptotic stem cells through fluorescence imaging.

The present invention relates to an imaging composition for imaging the urinary pathways, which comprises particles each independently comprising (a) a phospholipid, wherein a near infrared (NIR) fluorescent probe is non-covalently linked to said particle; or (b) an inclusion complex of said NIR fluorescent probe and either an hydroxyalkyl- or sulphoalkylether-cyclodextrin; and to a method of use.